Signalling in pancreatic cancer: from pathways to therapy

Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma

(2023) Jian Li et al.   Cancer Cell International

Targeting Src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models

(2023) Liangping Su et al.   Science Translational Medicine

A Novel Cuproptosis-Associated Gene Signature to Predict Prognosis in Patients with Pancreatic Cancer

(2023) Yan Du et al.   Biomed Research International

Chemotherapeutic drugs-induced pyroptosis mediated by gasdermin E promotes the progression and chemoresistance of pancreatic cancer

(2023) Shumin Li et al.   CANCER LETTERS

Ferroptosis regulates key signaling pathways in gastrointestinal tumors: Underlying mechanisms and therapeutic strategies

(2023) Ravichandiran Rabitha et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Starvation mediates pancreatic cancer cell sensitivity to ferroptosis via ERK1/2, JNK and changes in the cell mesenchymal state

(2022) Egle Zalyte et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results

(2022) Changsong Qi et al.   NATURE MEDICINE

Copper induces cell death by targeting lipoylated TCA cycle proteins

(2022) Peter Tsvetkov et al.   SCIENCE

Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.

(2022) Shukui Qin et al.   JOURNAL OF CLINICAL ONCOLOGY

Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer

(2022) Liqing Lu et al.   Cell Death Discovery

Cuproptosis-related gene index: A predictor for pancreatic cancer prognosis, immunotherapy efficacy, and chemosensitivity

(2022) Xufeng Huang et al.   Frontiers in Immunology

Construction of a Prognostic Model Based on Cuproptosis-Related lncRNA Signatures in Pancreatic Cancer

(2022) Wenkai Jiang et al.   Canadian Journal of Gastroenterology and Hepatology

Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer

(2022) Katrin J. Frank et al.   Cell Reports Medicine

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma

(2021) Cara Kenney et al.   INVESTIGATIONAL NEW DRUGS

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

(2021) Davide Melisi et al.   Journal for ImmunoTherapy of Cancer

Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling

(2021) Jing Cui et al.   MOLECULAR MEDICINE

Hedgehog signaling mechanism and role in cancer

(2021) Jin Jiang   SEMINARS IN CANCER BIOLOGY

Positive Crosstalk Between Hedgehog and NF-κB Pathways Is Dependent on KRAS Mutation in Pancreatic Ductal Adenocarcinoma

(2021) Yuqiong Wang et al.   Frontiers in Oncology

Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape

(2021) Ji Eun Lee et al.   CANCER LETTERS

Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study

(2021) Giuseppe Curigliano et al.   EUROPEAN JOURNAL OF CANCER

Pancreatic Adenocarcinoma Therapeutics Targeting RTK and TGF Beta Receptor

(2021) Hsin-Han Yang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Highlights on the Role of KRAS Mutations in Reshaping the Microenvironment of Pancreatic Adenocarcinoma

(2021) Shirin Hafezi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Pancreatic Cancer

(2021) Wungki Park et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Emerging strategies to target RAS signaling in human cancer therapy

(2021) Kun Chen et al.   Journal of Hematology & Oncology

Pancreatitis initiated pancreatic ductal adenocarcinoma: Pathophysiology explaining clinical evidence

(2021) Xufeng Tao et al.   PHARMACOLOGICAL RESEARCH

Oncogene APOL1 promotes proliferation and inhibits apoptosis via activating NOTCH1 signaling pathway in pancreatic cancer

(2021) Jiewei Lin et al.   Cell Death & Disease

Hedgehog/GLI Signaling Pathway: Transduction, Regulation, and Implications for Disease

(2021) Ashley N. Sigafoos et al.   Cancers

Engineering of an EpCAM-targeting cyclic peptide to improve the EpCAM-mediated cellular internalization and tumor accumulation of a peptide-fused antibody

(2021) Seong-Wook Park et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer

(2021) Ji Eun Lee et al.   Biomolecules & Therapeutics

LncRNA MIR99AHG mediated by FOXA1 modulates NOTCH2/Notch signaling pathway to accelerate pancreatic cancer through sponging miR-3129-5p and recruiting ELAVL1

(2021) Jin Xu et al.   Cancer Cell International

Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer

(2021) Jianhui Yang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

(2021) Daolin Tang et al.   Molecular Cancer

Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives

(2021) Xiaoqi Mao et al.   Molecular Cancer

RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging

(2021) Margie N. Sutton et al.   MOLECULAR IMAGING AND BIOLOGY

Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

(2021) Esther N. Pijnappel et al.   Cancers

Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma

(2020) Jia-qiao Fan et al.   Molecular Cancer

Hedgehog signaling promotes angiogenesis directly and indirectly in pancreatic cancer

(2020) Dirk Bausch et al.   ANGIOGENESIS

New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma

(2020) Ritu Raj Singh et al.   DRUGS

Gasdermin E suppresses tumour growth by activating anti-tumour immunity

(2020) Zhibin Zhang et al.   NATURE

A bioorthogonal system reveals antitumour immune function of pyroptosis

(2020) Qinyang Wang et al.   NATURE

Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as 1 st ‐line treatment in patients with metastatic pancreatic adenocarcinoma ( GATE 1)

(2020) Eric Assenat et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination

(2020) Ryan M. Carr et al.   PANCREATOLOGY

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers

(2020) Irem Ozkan-Dagliyan et al.   Cell Reports

Deubiquitinase USP18 promotes the progression of pancreatic cancer via enhancing the Notch1-c-Myc axis

(2020) Long Feng et al.   Aging-US

Quercetin suppresses pancreatic ductal adenocarcinoma progression via inhibition of SHH and TGF-β/Smad signaling pathways

(2020) Yangyang Guo et al.   CELL BIOLOGY AND TOXICOLOGY

CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer – Final results

(2020) M. Sinn et al.   EUROPEAN JOURNAL OF CANCER

Deciphering the Role of Innate Immune NF-ĸB Pathway in Pancreatic Cancer

(2020) Namrata Khurana et al.   Cancers

Hedgehog Signaling and Truncated GLI1 in Cancer

(2020) Daniel Doheny et al.   Cells

Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling

(2020) Shuo Chen et al.   Frontiers in Oncology

Glasdegib: First Global Approval

(2019) Sheridan M. Hoy   DRUGS

Triptolide suppresses pancreatic cancer cell proliferation by inhibiting hedgehog signaling pathway activity

(2019) Juanjuan Feng et al.   Science China-Life Sciences

AKT as a Therapeutic Target for Cancer

(2019) Mengqiu Song et al.   CANCER RESEARCH

microRNA-365a-3p inhibits c-Rel-mediated NF-κB signaling and the progression of pancreatic cancer

(2019) Libo Yin et al.   CANCER LETTERS

FDA Approval Summary: Glasdegib for newly-diagnosed acute myeloid leukemia

(2019) Kelly J. Norsworthy et al.   CLINICAL CANCER RESEARCH

Sequential Targeting TGF‐β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer

(2019) Yuanyuan Pei et al.   Small

Triptolide and Its Derivatives as Cancer Therapies

(2019) Pawan Noel et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Copper (II) Ions Activate Ligand-Independent Receptor Tyrosine Kinase (RTK) Signaling Pathway

(2019) Fang He et al.   Biomed Research International

Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models

(2019) Heng Sheng Sow et al.   Cells

RAS mutations in human cancers: Roles in precision medicine

(2019) Avaniyapuram Kannan Murugan et al.   SEMINARS IN CANCER BIOLOGY

Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts

(2019) Ela Elyada et al.   Cancer Discovery

A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

(2019) Zishuo Ian Hu et al.   Cancer Medicine

Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer

(2019) Niranjan Awasthi et al.   CANCER LETTERS

Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis

(2019) Tobias Forster et al.   ONCOLOGY

Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer

(2019) G. Aaron Hobbs et al.   Cancer Discovery

Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

(2019) Ana De Jesus-Acosta et al.   BRITISH JOURNAL OF CANCER

Precision medicine for human cancers with Notch signaling dysregulation (Review)

(2019) Masuko Katoh et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Ferroptosis is a lysosomal cell death process

(2018) Huan Gao et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma

(2018) Natalie Cook et al.   BRITISH JOURNAL OF CANCER

NF-κB in pancreatic cancer: Its key role in chemoresistance

(2018) Quanxiao Li et al.   CANCER LETTERS

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

(2018) C Massard et al.   ANNALS OF ONCOLOGY

Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-2-regulated apoptosis in pancreatic cancer cells

(2018) Rajpal S. Burmi et al.   CANCER BIOLOGY & THERAPY

KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer

(2018) Yeo Wool Kang et al.   CANCER LETTERS

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

(2018) Davide Melisi et al.   BRITISH JOURNAL OF CANCER

CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial

(2017) Marianne Sinn et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration

(2017) Seung-Min Shin et al.   Nature Communications

TGF-β in pancreatic cancer initiation and progression: two sides of the same coin

(2017) Wei Shen et al.   Cell and Bioscience

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy

(2017) Vincent Chung et al.   JAMA Oncology

Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers

(2017) Diána Brauswetter et al.   PLoS One

GDC-0449 improves the antitumor activity of nano-doxorubicin in pancreatic cancer in a fibroblast-enriched microenvironment

(2017) Quan Zhou et al.   Scientific Reports

Cyclopamine disrupts tumor extracellular matrix and improves the distribution and efficacy of nanotherapeutics in pancreatic cancer

(2016) Bo Zhang et al.   BIOMATERIALS

DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer

(2016) A Drouillard et al.   BRITISH JOURNAL OF CANCER

Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients

(2016) Motoki Miyazawa et al.   INTERNATIONAL JOURNAL OF CANCER

Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120

(2016) S.-H. Chen et al.   Cancer Discovery

LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer

(2016) Eliza Vakana et al.   Oncotarget

Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma

(2016) Matthew H. Wong et al.   NEOPLASIA

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

(2015) B. H. O'Neil et al.   ANNALS OF ONCOLOGY

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial†

(2015) C. S. Fuchs et al.   ANNALS OF ONCOLOGY

A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma

(2015) A. H. Ko et al.   CLINICAL CANCER RESEARCH

Sonidegib: First Global Approval

(2015) Celeste B. Burness   DRUGS

Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance

(2015) C. Duluc et al.   EMBO Molecular Medicine

mTOR Inhibition Induces EGFR Feedback Activation in Association with Its Resistance to Human Pancreatic Cancer

(2015) Feng Wei et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

(2015) Daniel V.T. Catenacci et al.   JOURNAL OF CLINICAL ONCOLOGY

Minnelide effectively eliminates CD133+ side population in pancreatic cancer

(2015) Alice Nomura et al.   Molecular Cancer

Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer

(2015) S Zhang et al.   ONCOGENE

Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status

(2015) Florence Huguet et al.   Targeted Oncology

GDC-0980-induced apoptosis is enhanced by autophagy inhibition in human pancreatic cancer cells

(2014) Jian-ying Tang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

(2014) L. Rahib et al.   CANCER RESEARCH

Mirk/dyrk1B kinase is upregulated following inhibition of mTOR

(2014) Xiaobing Deng et al.   CARCINOGENESIS

Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K-Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma

(2014) M. H. Wong et al.   CLINICAL CANCER RESEARCH

A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors

(2014) D. C. Smith et al.   CLINICAL CANCER RESEARCH

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

(2014) P. L. Bedard et al.   CLINICAL CANCER RESEARCH

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

(2014) Jeffrey R. Infante et al.   EUROPEAN JOURNAL OF CANCER

A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma

(2014) Ana De Jesus-Acosta et al.   INVESTIGATIONAL NEW DRUGS

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor

(2014) Melissa Dumble et al.   PLoS One

Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells

(2013) Ingrid Espinoza et al.   CANCER LETTERS

Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer

(2013) Shinichi Yabuuchi et al.   CANCER LETTERS

Cyclopamine, a Naturally Occurring Alkaloid, and Its Analogues May Find Wide Applications in Cancer Therapy

(2013) Haikuo Ma et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Trametinib: First Global Approval

(2013) Cameron J. M. Wright et al.   DRUGS

A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours

(2013) Jeffrey R. Infante et al.   EUROPEAN JOURNAL OF CANCER

Cetuximab: still an option in the treatment of pancreatic cancer?

(2013) Luca Faloppi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Inhibitors of Hedgehog acyltransferase block Sonic Hedgehog signaling

(2013) Elissaveta Petrova et al.   Nature Chemical Biology

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Disrupting Cytokine Signaling in Pancreatic Cancer

(2013) Christina Wu et al.   PANCREAS

Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical Models

(2013) Hua Zhong et al.   PLoS One

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer

(2012) A. Gonçalves et al.   ANNALS OF ONCOLOGY

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)

(2012) Volker Heinemann et al.   GUT

The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models

(2012) M. Mizuma et al.   MOLECULAR CANCER THERAPEUTICS

Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer

(2011) Karl-Hermann Schlingensiepen et al.   CANCER SCIENCE

Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

(2011) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice

(2011) Eleni Maniati et al.   JOURNAL OF CLINICAL INVESTIGATION

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

(2010) Milind M Javle et al.   BMC CANCER

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer

(2010) I Garrido-Laguna et al.   BRITISH JOURNAL OF CANCER

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

(2010) Dirk Strumberg et al.   INVESTIGATIONAL NEW DRUGS

Gefitinib Inhibits the Proliferation of Pancreatic Cancer Cells via Cell Cycle Arrest

(2009) Xiaohua Zhou et al.   Anatomical Record-Advances in Integrative Anatomy and Evolutionary Biology

Inhibition of γ-Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal Adenocarcinoma

(2009) Ruben Plentz et al.   GASTROENTEROLOGY

Pancreatic cancer: molecular pathogenesis and new therapeutic targets

(2009) Han H. Wong et al.   Nature Reviews Gastroenterology & Hepatology

Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer

(2009) J M Bailey et al.   ONCOGENE

Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent

(2008) C. R. Patra et al.   CANCER RESEARCH

Hedgehog: functions and mechanisms

(2008) M. Varjosalo et al.   GENES & DEVELOPMENT

Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer

(2008) Brian M. Wolpin et al.   JOURNAL OF CLINICAL ONCOLOGY